Work

KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

Year: 2008

Type: review

Abstract: The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) is the second Ru-based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (Hartinger et al., J. Inorg. Biochem. 2006, 100, 891-904), the experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction. The results of the early clinical development of KP1019 are summarized in which five out of six evaluated patients experienced disease stabilization with no severe side effects.

Source: Chemistry & Biodiversity

DOI: 10.1002/cbdv.200890195

Authors: Christian G. Hartinger, Michael A. Jakupec, Stefanie Zorbas‐Seifried, Michael Groessl, Alexander Egger, Walter Berger, Haralabos Zorbas, Paul J. Dyson, Bernhard K. Keppler

Institutions: University of Vienna, École Polytechnique Fédérale de Lausanne, Max Planck Institute of Biochemistry, Medical University of Vienna

Language: English

Topic: Metal complexes synthesis and properties

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2005723165

FWCI: 3.627

Cites: 84

Cited by: 851

Related to: 9